TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT06753331: A Multicenter Study to Evaluate Safety, Tolerability, and Clinical Responses of DSP-1083 Into Subjects With Parkinson's Disease

Sponsor: Sumitomo Pharma America, Inc. · Phase: PHASE1/PHASE2 · Area: CNS_NEUROLOGY · Target Enrollment: 25 pts

Competing Trials Overlap

4 Active Trials

Excess Burn Exposure

$725,560

Rescue Site Savings

+$494,700

Unlock Full NCT06753331 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06753331 Rescue Dossier →